
Neumora Therapeutics, Inc.: updates and filings
Price
$0.33
November 20, 2026Market cap $61M
What Ploutos Investor adds for Neumora Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operationsForm8-K
- Oct 30, 2026Delisting noticeForm8-K
- Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 14, 2026Results of operations, officer or director changeForm8-K
- Jul 27, 2026Other material eventsForm8-K
- Jun 15, 2026Material agreement entered, new material financial obligation, restructuring costs, Regulation FD disclosure, other material eventsForm8-K
- May 29, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 17, 2026Additional annual meeting materialFormDEFA14A
- Apr 17, 2026Annual meeting proxy statementFormDEF 14A
- Apr 1, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 30, 2026Shares registered for employeesFormS-8
- Mar 30, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 30, 2026Results of operationsForm8-K
- Feb 19, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 11, 2026Regulation FD disclosureForm8-K
- Jan 12, 2026Regulation FD disclosureForm8-K
- Jan 5, 2026Other material eventsForm8-K
- Nov 21, 2025Unregistered sale of sharesForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Oct 30, 2026 | 8-K | Delisting notice | Document |
| Aug 14, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 14, 2026 | 8-K | Results of operations, officer or director change | Document |
| Jul 27, 2026 | 8-K | Other material events | Document |
| Jun 15, 2026 | 8-K | Material agreement entered, new material financial obligation, restructuring costs, Regulation FD disclosure, other material events | Document |
| May 29, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 17, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 17, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 1, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 30, 2026 | S-8 | Shares registered for employees | Document |
| Mar 30, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 30, 2026 | 8-K | Results of operations | Document |
| Feb 19, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 11, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 12, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 5, 2026 | 8-K | Other material events | Document |
| Nov 21, 2025 | 8-K | Unregistered sale of shares | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 8, 2021.
The full analysis
What do Neumora Therapeutics's filings show?
The filings are where every one of Neumora Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.